Table 4.
Frequently Occurring Treatment-emergent Adverse Events During IRd Treatmenta (n = 84)
| TEAE | Grade, n (%) |
|
|---|---|---|
| Any Grade | Grade 3 | |
| Diarrhea | 34 (40) | 6 (7) |
| PN NECb | 25 (30) | 2 (2) |
| Fatigue | 20 (24) | 2 (2) |
| Nausea | 20 (24) | 2 (2) |
| Back pain | 16 (19) | 1 (1) |
| Constipation | 14 (17) | 0 (0) |
| Hypokalemia | 13 (15) | 2 (2) |
| Cough | 13 (15) | 0 (0) |
| Dizziness | 12 (14) | 1 (1) |
| Peripheral edema | 12 (14) | 0 (0) |
| Anemia | 11 (13) | 4 (5) |
| Arthralgia | 11 (13) | 0 (0) |
| Hypotension | 10 (12) | 2 (2) |
| Rash | 10 (12) | 2 (2) |
| Pneumonia | 9 (11) | 5 (6) |
| Vomiting | 9 (11) | 2 (2) |
| Decreased appetite | 8 (10) | 1 (1) |
| Decreased platelet count | 8 (10) | 1 (1) |
| Pyrexia | 8 (10) | 0 (0) |
| Syncope | 5 (6) | 5 (6) |
Abbreviations: IRd = ixazomib, lenalidomide, dexamethasone; PN NEC = peripheral neuropathy, not elsewhere classified.
a
Cutoffs for inclusion were ≥ 10% of patients with any grade or ≥ 5% of patients with grade 3 in the intent-to-treat population.
b
High-level term.